Publications by authors named "Yulia Sidi"

Claim this Profile
A
A phase I/II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma.
Marco A Salvino, Flavio A V Luisi, Mara A Pianovski, Franca Fagioli, Sidnei Epelman, Yulia Sidi

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, Anna Spreafico, Melanie Nordlinger, Yulia Sidi

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Yulia Sidi, Cassie Dong, Yujun Wu, Douglas V Faller

Leuk Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries.
Yulia Sidi, Yinghui Duan, Taeho Greg Rhee, Z Helen Wu

Res Social Adm Pharm· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis.
Yulia Sidi, Ofer Harel

Value Health· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incomplete data analysis of non-inferiority clinical trials: Difference between binomial proportions case.
Yulia Sidi, Ofer Harel

Contemp Clin Trials Commun· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The treatment of incomplete data: Reporting, analysis, reproducibility, and replicability.
Yulia Sidi, Ofer Harel

Soc Sci Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study.
Omar Khan, Navid Seraji-Bozorgzad, Fen Bao, Sara Razmjou, Christina Caon, Yulia Sidi

J Neuroimaging· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Olivier Rascol, Robert A Hauser, Fabrizio Stocchi, Cheryl J Fitzer-Attas, Yulia Sidi

Mov Disord· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
Jerry S Wolinsky, T Erik Borresen, Dennis W Dietrich, Daniel Wynn, Yulia Sidi

Mult Scler Relat Disord· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis